The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The changing standard of care in DLBCL
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, briefly discusses the standard of care for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and highlights how this may change with new data, such as that from the ongoing POLARIX trial (NCT03274492). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Merck, Gilead, BMS, Roche, Novartis, Prelude Therapeutics, Clinigen; Research Funding (to Institute): Merck, BeiGene, Janssen.
